Lurbinectedin is a medication used to treat metastatic small cell lung cancer (SCLC) that has progressed after treatment with other types of chemotherapy. The medication works by inhibiting the activity of RNA polymerase II, which is a critical enzyme for the transcription of DNA into RNA [1]. While Lurbinectedin is an effective treatment for SCLC, it can cause some side effects.

According to the Mayo Clinic, some of the most common side effects of Lurbinectedin include fatigue, nausea, vomiting, decreased appetite, constipation, and diarrhea. Other side effects that may occur less frequently include anemia, neutropenia, thrombocytopenia, and elevated liver enzymes [2].

The manufacturer of Lurbinectedin, Jazz Pharmaceuticals, provides additional information on the side effects of the medication. According to their website, some patients may experience serious side effects such as myelosuppression, which is a decrease in the production of blood cells, and hepatotoxicity, which is liver damage. Patients may also experience infusion-related reactions, which can include fever, chills, and low blood pressure [3].

In conclusion, while Lurbinectedin is an effective treatment for metastatic SCLC, it can cause some side effects. The most common side effects include fatigue, nausea, vomiting, decreased appetite, constipation, and diarrhea. Patients may also experience more serious side effects such as myelosuppression, hepatotoxicity, and infusion-related reactions. It is important for patients to discuss the potential side effects of Lurbinectedin with their healthcare provider and report any side effects they experience while taking the medication.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.mayoclinic.org/drugs-supplements/lurbinectedin-intravenous-route/side-effects/drg-20490804?p=1
[3] https://www.zepzelca.com/zepzelca-side-effects/